HAZ Stock Chart & Stats
€68.50
€1.50(2.24%)
At close: 4:00 PM EDT
€68.50
€1.50(2.24%)
Day’s Range― - ―
52-Week Range€39.80 - €78.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€3.55B
Enterprise Value€4.48K
Total Cash (Recent Filing)€223.38M
Total Debt (Recent Filing)€1.17B
Price to Earnings (P/E)44.1
Beta0.07
Next Earnings
Nov 05, 2026EPS Estimate
1.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.06
Shares Outstanding45,497,050
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.69
Price to Book (P/B)3.20
Price to Sales (P/S)1.91
P/FCF Ratio9.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€81.67Price Target Upside19.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)4.58
Revenue Forecast (FY)€1.22B
Bulls Say, Bears Say
Bulls Say
Installed-base Consumables ModelHaemonetics' business relies on device placements that drive recurring per-procedure consumable and service revenue. This creates durable, high-visibility annuity-like cash flow tied to procedure volumes, supporting revenue resiliency and margin leverage over multiple years as installed base grows.
Robust Free Cash Flow GenerationConsistently strong operating and free cash flow gives Haemonetics flexibility to fund R&D, pay down debt, and invest in commercial expansion without relying heavily on external financing. Durable FCF conversion underpins deleveraging and long-term strategic optionality, even if near-term working capital varies.
Diversified Product Momentum And Clinical ProgressBroad-based growth across Apheresis, MedSurg and IVT with new product rollouts and strong clinical data expands addressable markets and stickiness. Durable uptake of Persona PLUS and VASCADE clinical evidence can drive higher disposables use, market share gains and long-term recurring revenue expansion.
Bears Say
Elevated Balance-sheet LeverageHigher debt reduces financial flexibility and increases sensitivity to rising interest rates or cyclical earnings weakness. Elevated leverage constrains capital allocation choices, necessitates prioritizing deleveraging over opportunistic M&A or larger buybacks, and raises refinancing risk over the medium term.
Margin Compression And Higher Operating CostsSustained margin pressure from higher personnel, freight, acquisition-related costs, and FX can erode operating leverage. If structural cost inflation persists, it will limit the durability of profitability and free cash flow, forcing pricing, mix or efficiency actions that can take quarters to offset.
Inconsistent Revenue Trends And EPS VolatilityMixed top-line momentum and episodic EPS declines indicate sensitivity to procedure volumes, order timing and product mix. This variability can slow margin expansion and complicate planning, making sustained organic growth reliant on consistent adoption of new products and recovery in softer OEM or non-plasma Apheresis areas.
Haemonetics News
HAZ FAQ
What was Haemonetics Corp.’s price range in the past 12 months?
Haemonetics Corp. lowest stock price was €39.80 and its highest was €78.00 in the past 12 months.
What is Haemonetics Corp.’s market cap?
Haemonetics Corp.’s market cap is €3.55B.
When is Haemonetics Corp.’s upcoming earnings report date?
Haemonetics Corp.’s upcoming earnings report date is Nov 05, 2026 which is in 81 days.
How were Haemonetics Corp.’s earnings last quarter?
Haemonetics Corp. released its earnings results on Aug 06, 2026. The company reported €0.988 earnings per share for the quarter, beating the consensus estimate of €0.933 by €0.055.
Is Haemonetics Corp. overvalued?
According to Wall Street analysts Haemonetics Corp.’s price is currently Undervalued.
Does Haemonetics Corp. pay dividends?
Haemonetics Corp. does not currently pay dividends.
What is Haemonetics Corp.’s EPS estimate?
Haemonetics Corp.’s EPS estimate is 1.12.
How many shares outstanding does Haemonetics Corp. have?
Haemonetics Corp. has 45,497,050 shares outstanding.
What happened to Haemonetics Corp.’s price movement after its last earnings report?
Haemonetics Corp. reported an EPS of €0.988 in its last earnings report, beating expectations of €0.933. Following the earnings report the stock price went down -2.74%.
Which hedge fund is a major shareholder of Haemonetics Corp.?
Currently, no hedge funds are holding shares in DE:HAZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Haemonetics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€81.67 (19.23% Upside)
€81.67 (19.23% Upside)
Blogger Sentiment
Bullish
DE:HAZ Sentiment 80%
Sector Average 61%
Sector Average 61%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.08%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.24%
Trailing 12-Months
Company Description
Haemonetics Corp.
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
HAZ Company Deck
HAZ Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated broad‑based operational momentum: solid revenue and EPS growth, strong performance across core platforms (notably Plasma/Persona PLUS, Hemostasis, and Vascular Closure), upgraded fiscal guidance, and exceptional cash generation and debt paydown activity. Offsetting items include near‑term margin compression from prior‑year software recognition and sequential MedSurg revenue timing, higher operating costs, some OEM/ensoETM weakness in IVT, and continued external inflation/FX/headwind risks. Management emphasized disciplined, conservative guidance and prioritized deleveraging while keeping optionality for share repurchases and organic investment.View all DE:HAZ earnings summariesHAZ Stock 12 Month Forecast
Average Price Target
€81.67
▲(19.23% Upside)